View ValuationJacobio Pharmaceuticals Group 将来の成長Future 基準チェック /16 Jacobio Pharmaceuticals Groupは収益が増加すると予測されています。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長23.4%収益成長率17.7%将来の株主資本利益率3.20%アナリストカバレッジLow最終更新日12 Mar 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesBoard Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Director Bai Lu was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Mar 11Jacobio Pharmaceuticals Group Co., Ltd., Annual General Meeting, Jun 05, 2026Jacobio Pharmaceuticals Group Co., Ltd., Annual General Meeting, Jun 05, 2026.お知らせ • Feb 26Jacobio Pharmaceuticals Group Co., Ltd. to Report Fiscal Year 2025 Results on Mar 10, 2026Jacobio Pharmaceuticals Group Co., Ltd. announced that they will report fiscal year 2025 results on Mar 10, 2026お知らせ • Oct 24Jacobio Pharma Presents Pre-Clinical Data of Pan-KRAS Inhibitor (JAB-23E73) at AACR-NCI-EORTC International ConferenceJacobio Pharma announced that it presented the pre-clinical data of its internally discovered pan-KRAS inhibitor JAB-23E73 in a poster presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The pre-clinical results demonstrated that JAB-23E73 is a highly potent pan-KRAS (ON/OFF) inhibitor with strong selectivity that spares HRAS and NRAS inhibition. The compound exhibits superior antitumor activity across multiple cancer types harboring different KRAS driver mutations or amplification. In KRAS-driven mouse tumor models, JAB-23E73 induced tumor regression without causing significant body weight loss, indicating good tolerability and a wide therapeutic window. The compound also showed a favorable pharmacokinetic profile for oral administration and exhibited plasma drug concentration-dependent intratumoral p-ERK inhibition. Phase I clinical trials of JAB-23E73 are currently ongoing in both China and the United States for patients with advanced solid tumors harboring KRAS gene alterations.お知らせ • Aug 19Jacobio Pharmaceuticals Group Co., Ltd. to Report First Half, 2025 Results on Aug 29, 2025Jacobio Pharmaceuticals Group Co., Ltd. announced that they will report first half, 2025 results on Aug 29, 2025お知らせ • Jul 15Jacobio Pharmaceuticals Group Co., Ltd. (SEHK:1167) commences an Equity Buyback for 78,873,528 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2025.Jacobio Pharmaceuticals Group Co., Ltd. (SEHK:1167) commences share repurchases on July 15, 2025, under the program mandated by the shareholders in the Annual General Meeting held on June 10, 2025. As per the mandate, the company is authorized to repurchase up to 78,873,528 shares, representing 10% of its issued share capital. The repurchases will lead to an enhancement of the net asset value per share and/or earnings per share for the company. The repurchases will be made out of the funds legally available for such purpose in accordance with the Articles of Association and the applicable laws of the Cayman Islands and the Listing Rules. The company may cancel such repurchased shares or hold them as treasury shares on or after the Rule Amendment Effective Date. The authority shall expire at the earliest of the next Annual General Meeting, the date on which the next Annual General Meeting is required to be held or the date on which the authority is varied or revoked in a General Meeting. As of June 10, 2025, the company has 791,755,080 shares in issue. On July 14, 2025, the company announces a share repurchase program. Under the program, the company will repurchase up to HKD 100 million worth of its shares. The repurchase price of each share shall be no more than 5% higher than the average closing market price for the shares over the five trading days immediately preceding each repurchase. The company intends to fund the program from its own financial resources.お知らせ • Jul 03Jacobio Pharma Submits Phase I/II Investigational New Drug Application for its Bet Inhibitor JAB-8263 for the Treatment of Autoimmune Diseases to the Center for Drug Evaluation in ChinaJacobio Pharma announced that it has submitted the Phase I/II Investigational New Drug (IND) application for its BET inhibitor JAB-8263 for the treatment of autoimmune diseases to the Center for Drug Evaluation (CDE) in China and has been accepted. According to new regulatory guidelines, the review of JAB-8263's IND application is expected to be completed within 30 working days. Previously, Jacobio has completed phase I clinical trials of JAB-8263 for solid tumor and hematological malignancies in both China and the United States. Data presented at the 2024 American Society of Hematology (ASH) Annual Meeting showed that JAB-8263 demonstrated good tolerability.お知らせ • Jul 02Jacobio Completes the First Patient Dage in the Phase I/IIa Clinical Trial of Pan-KRAS Inhibitor JAB-23E73 in U.SThe board of directors of JACOBIO PHARMACEUTICALS Group CO., LTD. announced that the Company has completed the first patient dosage in the phase I/IIa clinical trial of its in-house developed pan-KRAS inhibitor JAB-23E73 in U.S. In parallel, the dose-escalation study in China is progressing as planned. KRAS mutations represent one of the most common oncogenic alterations in tumors, occurring in approximately 23%-25% of cancer patients. The mutation frequency is particularly high in pancreatic cancer (90%), colorectal cancer (40%), and non-small cell lung cancer (30%). An estimated 2.7 million newly diagnosed cancer patients worldwide are found to have tumor with KRAS mutations, underscoring the significant unmet need and the potential benefit of pan-KRAS inhibitors for this patient population. JAB-23E73 demonstrates high selectivity for KRAS, effectively inhibiting both the active ("On") and inactive ("Off") states of KRAS, with no inhibition to HRAS or NRAS. As an oral KRAS inhibitor, JAB-23E73 has shown a favorable pharmacokinetic profile and promising anti-tumor activity in preclinical models.お知らせ • Mar 20+ 1 more updateJacobio Pharmaceuticals Group Co., Ltd. Announces Board and Composition of the Nomination Committee ChangesThe Board of Jacobio Pharmaceuticals Group Co., Ltd. announced that, Ms. Yunyan HU, an executive Director, has been appointed as a member of the Nomination Committee with effect from March 19, 2025 upon the recommendation of the Nomination Committee. Dr. Te-li CHEN, a non-executive Director, has ceased to be a member of the Nomination Committee with effect from March 19, 2025. Following the above changes, the Nomination Committee comprises Dr. Yinxiang WANG as the chairman, and Ms. Yunyan HU, Dr. Ruilin SONG, Dr. Ge WU and Dr. Bai LU as members.お知らせ • Mar 07Jacobio Pharmaceuticals Group Co., Ltd. to Report Fiscal Year 2024 Results on Mar 19, 2025Jacobio Pharmaceuticals Group Co., Ltd. announced that they will report fiscal year 2024 results on Mar 19, 2025お知らせ • Jan 07Jacobio Pharma Announces the Registrational Clinical Data of Glecirasib Was Published in Nature MedicineJacobio Pharma announced that the data from a registrational clinical trial of its independently developed KRAS G12C inhibitor glecirasib has been published in Nature Medicine (impact factor 58.7). In the article, Jaocbio disclosed, for the first time, the complete dataset of glecirasib in KRAS G12C mutant non-small cell lung cancer patients in the second line or above setting. The pivotal phase II trial of glecirasib monotherapy demonstrated impressive efficacy, including the confirmed objective response rate of 47.9% (56/117), a median progression-free survival of 8.2 months, and a median overall survival of 13.6 months. Glecirasib has a manageable safety profile. Gleciasib has a favorable gastrointestinal safety profile compared with other KRAS G12C inhibitors. The new drug application of glecirasib is currently under evaluation by the Center for Drug Evaluation of the National Medical Products Administration of China, and has been granted Priority Review Designation.お知らせ • Dec 09Jacobio Pharma Presents preliminary Data on BET Inhibitor for Myelofibrosis at 2024 ASHJacobio Pharmaceuticals Group Co., Ltd. presented preliminary Phase I data of BET inhibitor JAB-8263 to treat myelofibrosis (MF) at the 2024 ASH (American Society of Hematology) Annual Meeting in San Diego, California. The data showed that JAB-8263 was well tolerated with Recommended Phase 2 Dose (RP2D) being 0.3mg QD. The preliminary efficacy data for JAB-8263 monotherapy in MF are promising, as most patients demonstrated spleen volume reduction (SVR) and total symptom score (TSS) reduction. As of the data cutoff date of October 17, 2024, 16 patients with intermediate-/high-risk MF have been enrolled, and 13 patients have undergone at least one post-treatment efficacy assessment. All patients showed a mean SVR-19.95% at week 24 and -26.16% at best response. Two patients achieved =35% SVR, and an SVR of -34.9% was observed in one patient. Six of ten (60%) patients experienced a =50% reduction in TSS at week 24. The best response of SVR in 2 of 8 patients (JAK inhibitors-treated) was -41.2% and -34.9%, respectively. At week 24, 3 of 6 (50%) patients (JAK inhibitors-treated) achieved TSS50.お知らせ • Nov 27Jacobio Pharmaceuticals Group Co., Ltd. Completes First Patient Dose in the Phase I/IIa Clinical Trial of Pan-Kras Inhibitor Jab-23E73 in ChinaThe board of directors of JACOBIO PHARMACEUTICALS Group CO., LTD. announced that the Company has completed the first patient dosage in the phase I/IIa clinical trial of its in-house developed pan-KRAS Inhibitor JAB-23E73 in China. KRAS is widely present in a variety of tumor mutations. About 23%-25% of cancer patients have KRAS mutations. About 2.7 million tumor patients with KRAS-related mutations are added each year worldwide and are expected to benefit from pan-KRAS inhibitor. JAB-23E73 can inhibit both the active ("On") and inactive ("Off") states of KRAS and with no obvious inhibition to HRAS or NRAS. As an oral KRAS inhibitor, JAB-23E73's preclinical data has shown a good pharmacokinetic profile.お知らせ • Oct 09Jacobio Pharmaceuticals Group Co., Ltd. Presents the Pre-Clinical Data of Shp2 Inhibitorjab-3312 in Combination with Kras G12c Inhibitor Glecirasibat the Fifth Ras Initiative Symposium 2024Jacobio Pharmaceuticals Group Co., Ltd. announced that the company presented the pre-clinical data of SHP2 inhibitor JAB-3312 in combo with KRAS G12C inhibitor Glecirasib as form of poster at the Fifth RAS Initiative Symposium 2024. The data showed that Glecirasib and JAB-3312 demonstrate potent anti-tumor effect both in vitro and in vivo, and JAB-3312 enhances the anti-tumor effect of Glecirasib. Representative patient cases were also included in the poster. The clinical data of the combination of JAB-3312 and Glecirasib also verified the above preclinical conclusions. The poster released by Jacobio at 2024 European Society for Medical Oncology (ESMO) Congress (ESMO 2024) showed that the confirmed objective response rate (cORR) of Glecirasib and JAB-3312 as first-line treatment for non-small cell lung cancer (NSCLC) was 70.6% (N=102), and the median progression-free survival (mPFS) remained stable at 12.2 months. Currently, a phase III registration clinical trial of JAB-3312 and Glecirasib for the treatment of first-line NSCLC harboring KRAS G12C mutation has been initiated in China. The Fifth RAS Initiative Symposium was held by Frederick National Laboratory which is affiliated with National Cancer Institute of the United States. Glecirasib (JAB-21822) is a KRAS G12C inhibitor developed by Jacobio. A number of clinical trials of Glecirasib are currently ongoing in China, the United States and Europe for patients with advanced solid tumors harboring KRAS G12C mutation. These include combination therapy trials with SHP2 inhibitor JAB-3312 in NSCLC and with cetuximab in colorectal cancer. The pancreatic cancer indication has obtained orphan drug designation in the United States and breakthrough therapy designation in China. JAB-3312 is a highly selective SHP2 allosteric inhibitor with best-in-class potential. Jacobio is currently conducting clinical trials of JAB-3312 in monotherapy and combination therapies with Glecirasib and other agents in China, the United States and Europe. The phase III study in combination with KRAS G12C inhibitor Glecirasib has been approved by the Center for Drug Evaluation of the National Medical Products Administration of China in February 2024.Reported Earnings • Oct 01First half 2024 earnings released: CN¥0.22 loss per share (vs CN¥0.22 loss in 1H 2023)First half 2024 results: CN¥0.22 loss per share (further deteriorated from CN¥0.22 loss in 1H 2023). Net loss: CN¥169.1m (loss widened 1.7% from 1H 2023). Revenue is expected to decline by 2.4% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 20%.お知らせ • Sep 23Jacobio Pharmaceuticals Group Co., Ltd. Receives Investigational New Drug (IND) Approval from the U.S. FDA for Pan-KRAS Inhibitor JAB-23E73JACOBIO PHARMACEUTICALS GROUP CO., LTD. announced that, the Food and Drug Administration of the United States has approved the Investigational New Drug application of its self-developed drug JAB-23E73 (Pan-KRAS Inhibitor), and plans to initiate phase I/IIa clinical trial in advanced solid tumor patients. The IND in China has been submitted to the Center for Drug Evaluation of the National Medical Product Administration of the PRC, and the clinical trial in China will be conducted after China IND approval. KRAS is widely present in a variety of tumor mutations. About 23%-25% of cancer patients have KRAS mutations. About 2.7 million tumor patients with KRAS-related mutations are added each year worldwide and are expected to benefit from pan-KRAS inhibitor. JAB-23E73 can inhibit both the active ("On") and inactive ("Off") states of KRAS and with no obvious inhibition to HRAS or NRAS. As an oral KRAS inhibitor, JAB-23E73's preclinical data has showed a good pharmacokinetic profile.お知らせ • Aug 30Jacobio Pharmaceuticals Group Co., Ltd. Announces Board ChangesJacobio Pharmaceuticals Group Co., Ltd. announced that Ms. Yanmin TANG (" Ms. Tang ") has tendered her resignation from the position as a non-executive Director with effect from August 30, 2024 due to her pursuit of other personal affairs. Accordingly, Ms. Tang will cease to be a member of the nomination committee of the Company (the "Nomination Committee") and the remuneration committee of the Company (the "Remuneration Committee") with effect from August 30, 2024. Ms. Tang confirmed that she The Board further announces that, Dr. Te-li CHEN, a non-executive Director, has been appointed as a member of the Nomination Committee and the Remuneration Committee in place of Ms. Tang with effect from August 30, 2024, respectively.お知らせ • Aug 20Jacobio Pharmaceuticals Group Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024Jacobio Pharmaceuticals Group Co., Ltd. announced that they will report first half, 2024 results on Aug 30, 2024お知らせ • Aug 07Jacobio Pharmaceuticals Group Co., Ltd. Completes First Patient Dosing in the Phase III Clinical Trial of Glecirasib in Combination with GlecirasibThe board of directors of Jacobio Pharmaceuticals Group Co., Ltd. announced that the Company has completed the first patient dosage in the Phase III clinical trial of KRAS G12C inhibitor Glecirasib in combination with the SHP2 inhibitor JAB-3312 versus standard care (chemotherapy plus anti-PD-1 antibody) in front-line KRAS G12C mutant non-small cell lung cancer (NSCLC). JAB-3312 is the first SHP2 inhibitor that entered a registration clinical trial globally. The new drug application (NDA) of Glecirasib monotherapy for the second-line and beyond NSCLC with KRAS G12C mutation was granted Priority Review designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China on May 21, 2024. According to data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2024, Glecirasib in combined with JAB-3312 resulted confirmed objective response rate (cORR) of 64.7% (66/102) and preliminary median progression-free survival (mPFS) of 12.2 months in the front-line NSCLC. The optimal dosing schedule Glecirasib at 800mg daily combined with JAB-33 12 at 2mg daily one week on and one week off resulted a cORR of 77.4% (24/31), and 54.8% (17/31) of patients achieved a deep response with tumors shrinking by more than 50%. Regarding on the safety data from all study patients the incidence of grade 3 or 4 treatment-related adverse events (TRAE) was 43.8%, and there was no treatment-related death. The overall safety is manageable. Glecirasib (JAB-21822) is a KRAS G12C inhibitor independently developed by Jacobio. A number of Phase I/II clinical trials of Glecirasib are currently ongoing in China, the United States and Europe for patients with advanced solid tumors harboring KRAS G12C mutation. These include a pivotal clinical trial in NSCLC in China, combination therapy trials with SHP2 inhibitor JAB -3312 in NSCLC and with cetuximab in colorectal cancer, and a registrational pivotal clinical trial of single agent for pancreatic cancer. The pancreatic cancer indication has obtained orphan drug designation in the United States and breakthrough therapy designation in China. JAB-3312 is a highly selective SHP2 allosteric inhibitor with the best-in-class potential. Jacobio is currently conducting multiple clinical trials of JAB-3312 in China, the United States, the United States and Europe, including the combination therapy trial with Glecirasib. The Phase III study in combination with KRAS G12C inhibitorlecirasib has been approved in China in February 2024.Board Change • Jun 26Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 7 experienced directors. No highly experienced directors. 3 independent directors (5 non-independent directors). Independent Non-Executive Director Bai Lu was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.業績と収益の成長予測DB:77V - アナリストの将来予測と過去の財務データ ( )CNY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2028317N/A-58103212/31/2027268N/A120210212/31/2026724N/A406488212/31/202554-146-213-211N/A9/30/2025127-96-128-124N/A6/30/2025201-46-44-37N/A3/31/2025179-101-65-55N/A12/31/2024156-156-86-74N/A9/30/202489-259-210-199N/A6/30/202423-362-334-325N/A3/31/202443-361-369-345N/A12/31/202364-359-403-364N/A9/30/202372-385-426-382N/A6/30/202381-410-449-400N/A3/31/202389-391-379-346N/A12/31/202296-372-309-292N/A9/30/2022123-332-230-218N/A6/30/2022150-292-151-145N/A3/31/2022151-297-155-146N/A12/31/2021153-301-159-147N/A9/30/2021348-570-70-56N/A6/30/2021544-8391836N/A3/31/2021515-1,1774357N/A12/31/2020486-1,5146879N/A9/30/2020243-1,298-37-30N/A6/30/2020N/A-1,082-141-139N/A3/31/2020N/A-753-129-126N/A12/31/2019N/A-425-116-113N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 77Vの予測収益成長が 貯蓄率 ( 1.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 77Vの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 77Vの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 77Vの収益 ( 17.7% ) German市場 ( 6.7% ) よりも速いペースで成長すると予測されています。高い収益成長: 77Vの収益 ( 17.7% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 77Vの 自己資本利益率 は、3年後には低くなると予測されています ( 3.2 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/02 15:29終値2026/07/02 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Jacobio Pharmaceuticals Group Co., Ltd. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Yu WuCMB International Securities LimitedLinhai ZhaoGoldman Sachs
Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Director Bai Lu was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Mar 11Jacobio Pharmaceuticals Group Co., Ltd., Annual General Meeting, Jun 05, 2026Jacobio Pharmaceuticals Group Co., Ltd., Annual General Meeting, Jun 05, 2026.
お知らせ • Feb 26Jacobio Pharmaceuticals Group Co., Ltd. to Report Fiscal Year 2025 Results on Mar 10, 2026Jacobio Pharmaceuticals Group Co., Ltd. announced that they will report fiscal year 2025 results on Mar 10, 2026
お知らせ • Oct 24Jacobio Pharma Presents Pre-Clinical Data of Pan-KRAS Inhibitor (JAB-23E73) at AACR-NCI-EORTC International ConferenceJacobio Pharma announced that it presented the pre-clinical data of its internally discovered pan-KRAS inhibitor JAB-23E73 in a poster presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The pre-clinical results demonstrated that JAB-23E73 is a highly potent pan-KRAS (ON/OFF) inhibitor with strong selectivity that spares HRAS and NRAS inhibition. The compound exhibits superior antitumor activity across multiple cancer types harboring different KRAS driver mutations or amplification. In KRAS-driven mouse tumor models, JAB-23E73 induced tumor regression without causing significant body weight loss, indicating good tolerability and a wide therapeutic window. The compound also showed a favorable pharmacokinetic profile for oral administration and exhibited plasma drug concentration-dependent intratumoral p-ERK inhibition. Phase I clinical trials of JAB-23E73 are currently ongoing in both China and the United States for patients with advanced solid tumors harboring KRAS gene alterations.
お知らせ • Aug 19Jacobio Pharmaceuticals Group Co., Ltd. to Report First Half, 2025 Results on Aug 29, 2025Jacobio Pharmaceuticals Group Co., Ltd. announced that they will report first half, 2025 results on Aug 29, 2025
お知らせ • Jul 15Jacobio Pharmaceuticals Group Co., Ltd. (SEHK:1167) commences an Equity Buyback for 78,873,528 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2025.Jacobio Pharmaceuticals Group Co., Ltd. (SEHK:1167) commences share repurchases on July 15, 2025, under the program mandated by the shareholders in the Annual General Meeting held on June 10, 2025. As per the mandate, the company is authorized to repurchase up to 78,873,528 shares, representing 10% of its issued share capital. The repurchases will lead to an enhancement of the net asset value per share and/or earnings per share for the company. The repurchases will be made out of the funds legally available for such purpose in accordance with the Articles of Association and the applicable laws of the Cayman Islands and the Listing Rules. The company may cancel such repurchased shares or hold them as treasury shares on or after the Rule Amendment Effective Date. The authority shall expire at the earliest of the next Annual General Meeting, the date on which the next Annual General Meeting is required to be held or the date on which the authority is varied or revoked in a General Meeting. As of June 10, 2025, the company has 791,755,080 shares in issue. On July 14, 2025, the company announces a share repurchase program. Under the program, the company will repurchase up to HKD 100 million worth of its shares. The repurchase price of each share shall be no more than 5% higher than the average closing market price for the shares over the five trading days immediately preceding each repurchase. The company intends to fund the program from its own financial resources.
お知らせ • Jul 03Jacobio Pharma Submits Phase I/II Investigational New Drug Application for its Bet Inhibitor JAB-8263 for the Treatment of Autoimmune Diseases to the Center for Drug Evaluation in ChinaJacobio Pharma announced that it has submitted the Phase I/II Investigational New Drug (IND) application for its BET inhibitor JAB-8263 for the treatment of autoimmune diseases to the Center for Drug Evaluation (CDE) in China and has been accepted. According to new regulatory guidelines, the review of JAB-8263's IND application is expected to be completed within 30 working days. Previously, Jacobio has completed phase I clinical trials of JAB-8263 for solid tumor and hematological malignancies in both China and the United States. Data presented at the 2024 American Society of Hematology (ASH) Annual Meeting showed that JAB-8263 demonstrated good tolerability.
お知らせ • Jul 02Jacobio Completes the First Patient Dage in the Phase I/IIa Clinical Trial of Pan-KRAS Inhibitor JAB-23E73 in U.SThe board of directors of JACOBIO PHARMACEUTICALS Group CO., LTD. announced that the Company has completed the first patient dosage in the phase I/IIa clinical trial of its in-house developed pan-KRAS inhibitor JAB-23E73 in U.S. In parallel, the dose-escalation study in China is progressing as planned. KRAS mutations represent one of the most common oncogenic alterations in tumors, occurring in approximately 23%-25% of cancer patients. The mutation frequency is particularly high in pancreatic cancer (90%), colorectal cancer (40%), and non-small cell lung cancer (30%). An estimated 2.7 million newly diagnosed cancer patients worldwide are found to have tumor with KRAS mutations, underscoring the significant unmet need and the potential benefit of pan-KRAS inhibitors for this patient population. JAB-23E73 demonstrates high selectivity for KRAS, effectively inhibiting both the active ("On") and inactive ("Off") states of KRAS, with no inhibition to HRAS or NRAS. As an oral KRAS inhibitor, JAB-23E73 has shown a favorable pharmacokinetic profile and promising anti-tumor activity in preclinical models.
お知らせ • Mar 20+ 1 more updateJacobio Pharmaceuticals Group Co., Ltd. Announces Board and Composition of the Nomination Committee ChangesThe Board of Jacobio Pharmaceuticals Group Co., Ltd. announced that, Ms. Yunyan HU, an executive Director, has been appointed as a member of the Nomination Committee with effect from March 19, 2025 upon the recommendation of the Nomination Committee. Dr. Te-li CHEN, a non-executive Director, has ceased to be a member of the Nomination Committee with effect from March 19, 2025. Following the above changes, the Nomination Committee comprises Dr. Yinxiang WANG as the chairman, and Ms. Yunyan HU, Dr. Ruilin SONG, Dr. Ge WU and Dr. Bai LU as members.
お知らせ • Mar 07Jacobio Pharmaceuticals Group Co., Ltd. to Report Fiscal Year 2024 Results on Mar 19, 2025Jacobio Pharmaceuticals Group Co., Ltd. announced that they will report fiscal year 2024 results on Mar 19, 2025
お知らせ • Jan 07Jacobio Pharma Announces the Registrational Clinical Data of Glecirasib Was Published in Nature MedicineJacobio Pharma announced that the data from a registrational clinical trial of its independently developed KRAS G12C inhibitor glecirasib has been published in Nature Medicine (impact factor 58.7). In the article, Jaocbio disclosed, for the first time, the complete dataset of glecirasib in KRAS G12C mutant non-small cell lung cancer patients in the second line or above setting. The pivotal phase II trial of glecirasib monotherapy demonstrated impressive efficacy, including the confirmed objective response rate of 47.9% (56/117), a median progression-free survival of 8.2 months, and a median overall survival of 13.6 months. Glecirasib has a manageable safety profile. Gleciasib has a favorable gastrointestinal safety profile compared with other KRAS G12C inhibitors. The new drug application of glecirasib is currently under evaluation by the Center for Drug Evaluation of the National Medical Products Administration of China, and has been granted Priority Review Designation.
お知らせ • Dec 09Jacobio Pharma Presents preliminary Data on BET Inhibitor for Myelofibrosis at 2024 ASHJacobio Pharmaceuticals Group Co., Ltd. presented preliminary Phase I data of BET inhibitor JAB-8263 to treat myelofibrosis (MF) at the 2024 ASH (American Society of Hematology) Annual Meeting in San Diego, California. The data showed that JAB-8263 was well tolerated with Recommended Phase 2 Dose (RP2D) being 0.3mg QD. The preliminary efficacy data for JAB-8263 monotherapy in MF are promising, as most patients demonstrated spleen volume reduction (SVR) and total symptom score (TSS) reduction. As of the data cutoff date of October 17, 2024, 16 patients with intermediate-/high-risk MF have been enrolled, and 13 patients have undergone at least one post-treatment efficacy assessment. All patients showed a mean SVR-19.95% at week 24 and -26.16% at best response. Two patients achieved =35% SVR, and an SVR of -34.9% was observed in one patient. Six of ten (60%) patients experienced a =50% reduction in TSS at week 24. The best response of SVR in 2 of 8 patients (JAK inhibitors-treated) was -41.2% and -34.9%, respectively. At week 24, 3 of 6 (50%) patients (JAK inhibitors-treated) achieved TSS50.
お知らせ • Nov 27Jacobio Pharmaceuticals Group Co., Ltd. Completes First Patient Dose in the Phase I/IIa Clinical Trial of Pan-Kras Inhibitor Jab-23E73 in ChinaThe board of directors of JACOBIO PHARMACEUTICALS Group CO., LTD. announced that the Company has completed the first patient dosage in the phase I/IIa clinical trial of its in-house developed pan-KRAS Inhibitor JAB-23E73 in China. KRAS is widely present in a variety of tumor mutations. About 23%-25% of cancer patients have KRAS mutations. About 2.7 million tumor patients with KRAS-related mutations are added each year worldwide and are expected to benefit from pan-KRAS inhibitor. JAB-23E73 can inhibit both the active ("On") and inactive ("Off") states of KRAS and with no obvious inhibition to HRAS or NRAS. As an oral KRAS inhibitor, JAB-23E73's preclinical data has shown a good pharmacokinetic profile.
お知らせ • Oct 09Jacobio Pharmaceuticals Group Co., Ltd. Presents the Pre-Clinical Data of Shp2 Inhibitorjab-3312 in Combination with Kras G12c Inhibitor Glecirasibat the Fifth Ras Initiative Symposium 2024Jacobio Pharmaceuticals Group Co., Ltd. announced that the company presented the pre-clinical data of SHP2 inhibitor JAB-3312 in combo with KRAS G12C inhibitor Glecirasib as form of poster at the Fifth RAS Initiative Symposium 2024. The data showed that Glecirasib and JAB-3312 demonstrate potent anti-tumor effect both in vitro and in vivo, and JAB-3312 enhances the anti-tumor effect of Glecirasib. Representative patient cases were also included in the poster. The clinical data of the combination of JAB-3312 and Glecirasib also verified the above preclinical conclusions. The poster released by Jacobio at 2024 European Society for Medical Oncology (ESMO) Congress (ESMO 2024) showed that the confirmed objective response rate (cORR) of Glecirasib and JAB-3312 as first-line treatment for non-small cell lung cancer (NSCLC) was 70.6% (N=102), and the median progression-free survival (mPFS) remained stable at 12.2 months. Currently, a phase III registration clinical trial of JAB-3312 and Glecirasib for the treatment of first-line NSCLC harboring KRAS G12C mutation has been initiated in China. The Fifth RAS Initiative Symposium was held by Frederick National Laboratory which is affiliated with National Cancer Institute of the United States. Glecirasib (JAB-21822) is a KRAS G12C inhibitor developed by Jacobio. A number of clinical trials of Glecirasib are currently ongoing in China, the United States and Europe for patients with advanced solid tumors harboring KRAS G12C mutation. These include combination therapy trials with SHP2 inhibitor JAB-3312 in NSCLC and with cetuximab in colorectal cancer. The pancreatic cancer indication has obtained orphan drug designation in the United States and breakthrough therapy designation in China. JAB-3312 is a highly selective SHP2 allosteric inhibitor with best-in-class potential. Jacobio is currently conducting clinical trials of JAB-3312 in monotherapy and combination therapies with Glecirasib and other agents in China, the United States and Europe. The phase III study in combination with KRAS G12C inhibitor Glecirasib has been approved by the Center for Drug Evaluation of the National Medical Products Administration of China in February 2024.
Reported Earnings • Oct 01First half 2024 earnings released: CN¥0.22 loss per share (vs CN¥0.22 loss in 1H 2023)First half 2024 results: CN¥0.22 loss per share (further deteriorated from CN¥0.22 loss in 1H 2023). Net loss: CN¥169.1m (loss widened 1.7% from 1H 2023). Revenue is expected to decline by 2.4% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 20%.
お知らせ • Sep 23Jacobio Pharmaceuticals Group Co., Ltd. Receives Investigational New Drug (IND) Approval from the U.S. FDA for Pan-KRAS Inhibitor JAB-23E73JACOBIO PHARMACEUTICALS GROUP CO., LTD. announced that, the Food and Drug Administration of the United States has approved the Investigational New Drug application of its self-developed drug JAB-23E73 (Pan-KRAS Inhibitor), and plans to initiate phase I/IIa clinical trial in advanced solid tumor patients. The IND in China has been submitted to the Center for Drug Evaluation of the National Medical Product Administration of the PRC, and the clinical trial in China will be conducted after China IND approval. KRAS is widely present in a variety of tumor mutations. About 23%-25% of cancer patients have KRAS mutations. About 2.7 million tumor patients with KRAS-related mutations are added each year worldwide and are expected to benefit from pan-KRAS inhibitor. JAB-23E73 can inhibit both the active ("On") and inactive ("Off") states of KRAS and with no obvious inhibition to HRAS or NRAS. As an oral KRAS inhibitor, JAB-23E73's preclinical data has showed a good pharmacokinetic profile.
お知らせ • Aug 30Jacobio Pharmaceuticals Group Co., Ltd. Announces Board ChangesJacobio Pharmaceuticals Group Co., Ltd. announced that Ms. Yanmin TANG (" Ms. Tang ") has tendered her resignation from the position as a non-executive Director with effect from August 30, 2024 due to her pursuit of other personal affairs. Accordingly, Ms. Tang will cease to be a member of the nomination committee of the Company (the "Nomination Committee") and the remuneration committee of the Company (the "Remuneration Committee") with effect from August 30, 2024. Ms. Tang confirmed that she The Board further announces that, Dr. Te-li CHEN, a non-executive Director, has been appointed as a member of the Nomination Committee and the Remuneration Committee in place of Ms. Tang with effect from August 30, 2024, respectively.
お知らせ • Aug 20Jacobio Pharmaceuticals Group Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024Jacobio Pharmaceuticals Group Co., Ltd. announced that they will report first half, 2024 results on Aug 30, 2024
お知らせ • Aug 07Jacobio Pharmaceuticals Group Co., Ltd. Completes First Patient Dosing in the Phase III Clinical Trial of Glecirasib in Combination with GlecirasibThe board of directors of Jacobio Pharmaceuticals Group Co., Ltd. announced that the Company has completed the first patient dosage in the Phase III clinical trial of KRAS G12C inhibitor Glecirasib in combination with the SHP2 inhibitor JAB-3312 versus standard care (chemotherapy plus anti-PD-1 antibody) in front-line KRAS G12C mutant non-small cell lung cancer (NSCLC). JAB-3312 is the first SHP2 inhibitor that entered a registration clinical trial globally. The new drug application (NDA) of Glecirasib monotherapy for the second-line and beyond NSCLC with KRAS G12C mutation was granted Priority Review designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China on May 21, 2024. According to data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2024, Glecirasib in combined with JAB-3312 resulted confirmed objective response rate (cORR) of 64.7% (66/102) and preliminary median progression-free survival (mPFS) of 12.2 months in the front-line NSCLC. The optimal dosing schedule Glecirasib at 800mg daily combined with JAB-33 12 at 2mg daily one week on and one week off resulted a cORR of 77.4% (24/31), and 54.8% (17/31) of patients achieved a deep response with tumors shrinking by more than 50%. Regarding on the safety data from all study patients the incidence of grade 3 or 4 treatment-related adverse events (TRAE) was 43.8%, and there was no treatment-related death. The overall safety is manageable. Glecirasib (JAB-21822) is a KRAS G12C inhibitor independently developed by Jacobio. A number of Phase I/II clinical trials of Glecirasib are currently ongoing in China, the United States and Europe for patients with advanced solid tumors harboring KRAS G12C mutation. These include a pivotal clinical trial in NSCLC in China, combination therapy trials with SHP2 inhibitor JAB -3312 in NSCLC and with cetuximab in colorectal cancer, and a registrational pivotal clinical trial of single agent for pancreatic cancer. The pancreatic cancer indication has obtained orphan drug designation in the United States and breakthrough therapy designation in China. JAB-3312 is a highly selective SHP2 allosteric inhibitor with the best-in-class potential. Jacobio is currently conducting multiple clinical trials of JAB-3312 in China, the United States, the United States and Europe, including the combination therapy trial with Glecirasib. The Phase III study in combination with KRAS G12C inhibitorlecirasib has been approved in China in February 2024.
Board Change • Jun 26Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 7 experienced directors. No highly experienced directors. 3 independent directors (5 non-independent directors). Independent Non-Executive Director Bai Lu was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.